<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lancet Infect Dis</journal-id><journal-title-group><journal-title>The Lancet Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1473-3099</issn><issn pub-type="epub">1474-4457</issn><publisher><publisher-name>Elsevier Science, The Lancet Pub. Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24161233</article-id><article-id pub-id-type="pmc">3895323</article-id><article-id pub-id-type="publisher-id">S1473-3099(13)70295-0</article-id><article-id pub-id-type="doi">10.1016/S1473-3099(13)70295-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Derde</surname><given-names>Lennie P G</given-names></name><degrees>MD</degrees><email>lderde@umcutrecht.nl</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>Ben S</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Goossens</surname><given-names>Herman</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Malhotra-Kumar</surname><given-names>Surbhi</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Willems</surname><given-names>Rob J L</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Gniadkowski</surname><given-names>Marek</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Hryniewicz</surname><given-names>Waleria</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Empel</surname><given-names>Joanna</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Dautzenberg</surname><given-names>Mirjam J D</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Annane</surname><given-names>Djillali</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Arag&#x000e3;o</surname><given-names>Irene</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Chalfine</surname><given-names>Annie</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><name><surname>Dumpis</surname><given-names>Uga</given-names></name><degrees>MD</degrees><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Esteves</surname><given-names>Francisco</given-names></name><degrees>MD</degrees><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author"><name><surname>Giamarellou</surname><given-names>Helen</given-names></name><degrees>PhD</degrees><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Muzlovic</surname><given-names>Igor</given-names></name><degrees>PhD</degrees><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Nardi</surname><given-names>Giuseppe</given-names></name><degrees>PhD</degrees><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author"><name><surname>Petrikkos</surname><given-names>George L</given-names></name><degrees>PhD</degrees><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author"><name><surname>Tomic</surname><given-names>Viktorija</given-names></name><degrees>PhD</degrees><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;</surname><given-names>Antonio Torres</given-names></name><degrees>PhD</degrees><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author"><name><surname>Stammet</surname><given-names>Pascal</given-names></name><degrees>MD</degrees><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author"><name><surname>Brun-Buisson</surname><given-names>Christian</given-names></name><degrees>PhD</degrees><xref rid="aff20" ref-type="aff">t</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Bonten</surname><given-names>Marc J M</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author"><collab>on behalf of the MOSAR WP3 Study Team</collab></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, Netherlands</aff><aff id="aff2"><label>b</label>Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands</aff><aff id="aff3"><label>c</label>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands</aff><aff id="aff4"><label>d</label>Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK</aff><aff id="aff5"><label>e</label>Department of Medical Microbiology, Vaccine &#x00026; Infectious Disease Institute, Antwerp University, University Hospital Antwerp, Antwerp, Belgium</aff><aff id="aff6"><label>f</label>Department of Molecular Microbiology, National Medicines Institute, Warsaw, Poland</aff><aff id="aff7"><label>g</label>Division of Microbiology and Infection Prevention, National Medicines Institute, Warsaw, Poland</aff><aff id="aff8"><label>h</label>Service de R&#x000e9;animation M&#x000e9;dicale, H&#x000f4;pital Raymond Poincar&#x000e9;, Garches, France</aff><aff id="aff9"><label>i</label>Polyvalent Intensive Care Unit, Central Hospital of Porto, Porto, Portugal</aff><aff id="aff10"><label>j</label>Infection Control Unit, Groupe Hospitalier Paris&#x02014;Saint Joseph, Paris, France</aff><aff id="aff11"><label>k</label>Department of Infection Control, Paul Stradins University Hospital, Riga, Latvia</aff><aff id="aff12"><label>l</label>ICU and Emergency Department, Centro Hospitalar Tr&#x000e1;s-os-Montes e Alto Douro, Vila Real, Portugal</aff><aff id="aff13"><label>m</label>4th Department of Internal Medicine, Athens University Medical School, Attikon General Hospital, Athens, Greece</aff><aff id="aff14"><label>n</label>Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia</aff><aff id="aff15"><label>o</label>Shock and Trauma Unit, Intensive Care Unit, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy</aff><aff id="aff16"><label>p</label>Infectious Diseases Unit, Laikon General Hospital, University of Athens, Athens, Greece</aff><aff id="aff17"><label>q</label>Laboratory for Respiratory Microbiology, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia</aff><aff id="aff18"><label>r</label>Pneumology Department, Hospital Clinic of Barcelona, Institut d'Investigacions Biom&#x000e8;diques August Pi i Sunyer, Ciber de Enfermedades Respiratorias, University of Barcelona, Barcelona, Spain</aff><aff id="aff19"><label>s</label>Intensive Care Unit, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg</aff><aff id="aff20"><label>t</label>Service de r&#x000e9;animation m&#x000e9;dicale and INSERM U657, Institut Pasteur, APHP GH Henri Mondor, Universit&#x000e9; Paris Est-Cr&#x000e9;teil, Creteil, France</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Lennie P G Derde, Department of Intensive Care Medicine, University Medical Center Utrecht, Universiteitsweg 100, 3584 CG Utrecht, Netherlands <email>lderde@umcutrecht.nl</email></corresp><fn id="fn1"><label>&#x02020;</label><p>Equally responsible for supervising the study</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>1</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was
					based on <pub-date pub-type="ppub">.--><pub-date pub-type="ppub"><month>1</month><year>2014</year></pub-date><volume>14</volume><issue>1</issue><fpage>31</fpage><lpage>39</lpage><permissions><copyright-statement>&#x000a9; 2014 Derde et al. Open Access article distributed under the terms of CC BY-NC-SA</copyright-statement><copyright-year>2014</copyright-year><license><license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p></license></permissions><abstract><title>Summary</title><sec><title>Background</title><p>Intensive care units (ICUs) are high-risk areas for transmission of antimicrobial-resistant bacteria, but no controlled study has tested the effect of rapid screening and isolation of carriers on transmission in settings with best-standard precautions. We assessed interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in European ICUs.</p></sec><sec><title>Methods</title><p>We did this study in three phases at 13 ICUs. After a 6 month baseline period (phase 1), we did an interrupted time series study of universal chlorhexidine body-washing combined with hand hygiene improvement for 6 months (phase 2), followed by a 12&#x02013;15 month cluster randomised trial (phase 3). ICUs were randomly assigned by computer generated randomisation schedule to either conventional screening (chromogenic screening for meticillin-resistant <italic>Staphylococcus aureus</italic> [MRSA] and vancomycin-resistant enterococci [VRE]) or rapid screening (PCR testing for MRSA and VRE and chromogenic screening for highly resistant Enterobacteriaceae [HRE]); with contact precautions for identified carriers. The primary outcome was acquisition of resistant bacteria per 100 patient-days at risk, for which we calculated step changes and changes in trends after the introduction of each intervention. We assessed acquisition by microbiological surveillance and analysed it with a multilevel Poisson segmented regression model. We compared screening groups with a likelihood ratio test that combined step changes and changes to trend. This study is registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="interrefs10">ClinicalTrials.gov</ext-link>, number <ext-link ext-link-type="uri" xlink:href="ctgov:NCT00976638" id="interrefs20">NCT00976638</ext-link>.</p></sec><sec><title>Findings</title><p>Seven ICUs were assigned to rapid screening and six to conventional screening. Mean hand hygiene compliance improved from 52% in phase 1 to 69% in phase 2, and 77% in phase 3. Median proportions of patients receiving chlorhexidine body-washing increased from 0% to 100% at the start of phase 2. For trends in acquisition of antimicrobial-resistant bacteria, weekly incidence rate ratio (IRR) was 0&#x000b7;976 (0&#x000b7;954&#x02013;0&#x000b7;999) for phase 2 and 1&#x000b7;015 (0&#x000b7;998&#x02013;1&#x000b7;032) for phase 3. For step changes, weekly IRR was 0&#x000b7;955 (0&#x000b7;676&#x02013;1&#x000b7;348) for phase 2 and 0&#x000b7;634 (0&#x000b7;349&#x02013;1&#x000b7;153) for phase 3. The decrease in trend in phase 2 was largely caused by changes in acquisition of MRSA (weekly IRR 0&#x000b7;925, 95% CI 0&#x000b7;890&#x02013;0&#x000b7;962). Acquisition was lower in the conventional screening group than in the rapid screening group, but did not differ significantly (p=0&#x000b7;06).</p></sec><sec><title>Interpretation</title><p>Improved hand hygiene plus unit-wide chlorhexidine body-washing reduced acquisition of antimicrobial-resistant bacteria, particularly MRSA. In the context of a sustained high level of compliance to hand hygiene and chlorhexidine bathings, screening and isolation of carriers do not reduce acquisition rates of multidrug-resistant bacteria, whether or not screening is done with rapid testing or conventional testing.</p></sec><sec><title>Funding</title><p>European Commission.</p></sec></abstract></article-meta></front><body><sec id="cesec10"><title>Introduction</title><p>Antimicrobial-resistant bacteria have become more widespread worldwide. Intensive care units (ICUs) are especially affected by three major groups of highly resistant pathogens&#x02014;meticillin-resistant <italic>Staphylococcus aureus</italic> (MRSA), vancomycin-resistant enterococci (VRE), and highly resistant (ie, resistant to third-generation or fourth-generation cephalosporins) Enterobacteriaceae (HRE). Controlling the spread of these organisms is a major public health challenge and often involves labour-intensive, protracted efforts. Several control measures have been advocated<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> including improved adherence to standard precautions,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> chlorhexidine body-washing,<xref rid="bib3 bib4 bib5 bib6 bib7 bib8 bib9" ref-type="bibr"><sup>3&#x02013;9</sup></xref> introduction of contact precautions for known carriers of antimicrobial-resistant bacteria and putting carriers in single-patient rooms,<xref rid="bib10 bib11" ref-type="bibr"><sup>10,11</sup></xref> and rapid detection of carriers at admission to ICU combined with isolation of carriers. However, evidence for these interventions is mainly based on small, quasi-experimental studies. Universal screening of patients at ICU admission for antimicrobial-resistant bacteria followed by contact precautions&#x02014;a costly and labour-intensive intervention&#x02014;remains the most controversial, with conflicting results precluding evidence-based recommendations.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p><p>No controlled study has tested the effect of rapid screening and isolation of carriers on colonisation with antimicrobial-resistant bacteria in settings that already have best standard precautions in place. We assessed the effect of different infection control strategies on acquisition of antimicrobial-resistant bacteria in ICUs.</p></sec><sec sec-type="methods" id="cesec20"><title>Methods</title><sec id="cesec30"><title>Study design and participants</title><p>We assessed 13 European ICUs between May, 2008, and April, 2011, in three phases. Implementation of costly and labour-intensive interventions&#x02014;eg, screening and isolation&#x02014;is probably futile in the absence of good basic hygiene. Therefore, after a 6 month baseline period (phase 1), we introduced a hygiene improvement programme at all ICUs in an interrupted time-series phase (phase 2) before beginning a cluster randomised, controlled phase (phase 3). In phase 2, we tested the effect of optimised hand hygiene plus unit-wide implementation of chlorhexidine body-washing on acquisition of antimicrobial-resistant bacteria. In phase 3, we tested the additional effect of screening followed by contact precautions for identified carriers, using either PCR for MRSA and VRE together with chromogenic screening for HRE (rapid screening), or chromogenic-based screening for MRSA and VRE only (conventional screening).</p><p>Interrupted time series are useful if a randomised controlled trial is not feasible.<xref rid="bib13 bib14" ref-type="bibr"><sup>13,14</sup></xref> We planned to use a stepped-wedge design for phase 2 but this proved impractical because of logistical and financial constraints. However, we did enrol ICUs consecutively to account for seasonal effects.</p><p>We aimed to include ICUs with a moderate to high proportion of resistant bacteria. Adult ICUs with at least eight beds were eligible, provided that&#x02014;of the ICU-acquired bacteraemias recorded in 2006 or 2007&#x02014;MRSA accounted for more than 10% of <italic>S aureus</italic> bacteraemias, VRE accounted for more than 5% of enterococcal bacteraemias, or extended-spectrum &#x003b2;-lactamase resistance accounted for more than 10% of Enterobacteriaceae bacteraemias.</p><p>Each institution's review board or national ethics committee approved the study protocol. Because the study involved very little risk of harm to patients, a waiver for informed consent was sought and granted for all participating centres.</p></sec><sec id="cesec40"><title>Randomisation and masking</title><p>After phase 2, the 13 ICUs were randomly assigned (1:1) to the rapid or conventional screening groups. The sequence for allocation was based on a computer-generated randomisation list, generated by an independent data manager who had no other role in the study. We did not match ICUs and no masking was used.</p></sec><sec sec-type="methods" id="cesec50"><title>Procedures</title><p>Surveillance swabs from perineum, nose, and wounds (if present) were obtained within 2 days of admission to the ICU, then twice per week for 3 weeks, then once per week thereafter, for all patients admitted to ICU for 3 days or more. All surveillance swabs were analysed locally, according to a standardised protocol (<xref rid="sec1" ref-type="sec">appendix</xref>). Chromogenic media was used for detection of MRSA (BBL CHROMagar MRSA II; Becton, Dickinson and Company, Franklin Lakes, NJ USA), BBL Enterococcosel Agar with vancomycin 8 &#x003bc;g/mL for detection of VRE (Becton, Dickinson and Company), and Brilliance ESBL 2 for detection of HRE (Oxoid, Cambridge, UK).<xref rid="bib15 bib16 bib17" ref-type="bibr"><sup>15&#x02013;17</sup></xref> In ICUs assigned to rapid screening, Xpert MRSA and Xpert VanA/VanB (Cepheid, Sunnyvale, CA, USA) were used additionally.<xref rid="bib18 bib19" ref-type="bibr"><sup>18,19</sup></xref></p><p>All microbiology laboratories were required to complete proficiency panels.<xref rid="bib20 bib21 bib22" ref-type="bibr"><sup>20&#x02013;22</sup></xref> All first isolates of MRSA, VRE, and HRE from surveillance cultures or blood were shipped to a central laboratory for species confirmation, susceptibility testing, and genotyping. To assess chlorhexidine resistance, the presence of <italic>qacA</italic> and <italic>qacB</italic> genes was investigated by PCR at the central laboratory.<xref rid="bib2 bib23" ref-type="bibr"><sup>2,23</sup></xref></p><p>After phase 1, we implemented a hand hygiene improvement programme and universal daily body-washing with 0&#x000b7;16 g/L chlorhexidine gluconate for 6 months (phase 2) in all ICUs. We derived the hand hygiene programme from the WHO's Five Moments for Hand Hygiene concept.<xref rid="bib2 bib3 bib4 bib5 bib6 bib7 bib24" ref-type="bibr"><sup>2&#x02013;7,24</sup></xref></p><p>These interventions continued in phase 3 alongside screening and contact precautions for carriers of antimicrobial-resistant bacteria (<xref rid="sec1" ref-type="sec">appendix</xref>). During phases 1 and 2, barrier precautions were based on pre-study local isolation protocols and were not part of the study interventions. During phase 1 and phase 2, surveillance cultures were stored and processed with a 2 month delay to maintain masking of ICU personnel to the colonisation status of patients. In phase 3, screening results were immediately disclosed to staff at ICUs. Time from acquisition of swabs to start of processing (time-to-test) and from start of test until reporting of results (time-to-result) were recorded for all surveillance cultures; the sum of both was the turn-around time of tests. Interventions likely to affect outcomes (eg, central-line-associated bloodstream infection bundles or ventilator-associated pneumonia bundles, selective digestive decontamination, enhanced antimicrobial stewardship, or mupirocin use) were not introduced during the study.</p><p>Patients' demographics, reason for ICU admission, length of stay in ICU and in hospital, disposition at discharge, and 28 day mortality, as well as occurrence of bactaeremia with <italic>S aureus</italic>, enterococci, and Enterobacteriaceae were recorded for all patients. We collected weekly point prevalence data for bed occupancy, staffing ratios, numbers of patients ventilated, invasive devices, and isolation details (<xref rid="sec1" ref-type="sec">appendix</xref>). Two research nurses in each ICU were centrally trained to do hand hygiene observations. 15 observation sessions, of 15&#x02013;30 min, were done every month throughout the study at the ICUs. The sessions were randomly scheduled within three 4 h periods (0800&#x02013;1200 h, 1200&#x02013;1600 h, and 1600&#x02013;2000 h).</p><p>We checked 10% of all electronic case report forms against data collected at each ICU, and checked all procedures for consistency once during phase 1 and once during phase 2. Data were collected through an online data entry system, consisting of an independently managed secure data processing centre, including plausibility checks for data entry.</p><p>Colonisation was defined as growth on chromogenic plates and acquisition was based on chromogenic agar results for all phases and both screening groups. If a patient was colonised according to the last screening culture, we assumed that colonisation persisted until discharge from ICU. If a patient was not colonised at the last screening culture, the period at risk ended on that day. Colonisation and bacteraemia were classed as ICU-acquired if detected on or after the third day of admission to the ICU, after a negative swab. We did not follow up patients after discharge from ICU.</p><p>The primary endpoint was the number of patients who acquired MRSA, VRE, or HRE carriage per 100 patient-days at risk in ICU. Secondary outcomes included incidence density rate of ICU-acquired colonisation and bacteraemia for each of MRSA, VRE, and HRE; compliance with hand hygiene practices; length of stay in ICU; length of stay in hospital; and 28 day mortality. The <xref rid="sec1" ref-type="sec">appendix</xref> shows further secondary outcomes.</p><p>Patients admitted for fewer than 3 days were not deemed at risk for ICU-acquired colonisation and bacteraemia, and were excluded from the analyses of ICU-acquired endpoints, though they were subject to the interventions. For secondary outcomes, patients were deemed at risk for acquisition of individual pathogens if not colonised or infected with that pathogen at hospital admission.</p></sec><sec id="cesec60"><title>Statistical analysis</title><p>We calculated that 960 patients per ICU would be needed to show a 10% absolute difference in the probability of colonisation between the randomised groups with a two-sided test and assuming a type I error of 0&#x000b7;05, a type II error of 0&#x000b7;2, and an intracluster correlation coefficient of 0&#x000b7;05. We assessed outcomes with a multilevel Poisson segmented regression analysis, allowing for random variation between ICUs for baseline levels and trends. We assessed both step changes in acquisition rate per 100 patient-days at risk and changes in trends of acquisition rate per 100 patient-days at risk (rate of change of the log weekly acquisition rate) after the introduction of each intervention.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref></p><p>Potential confounding factors&#x02014;calendar month and patient and ward characteristics&#x02014;were fitted as covariates. We did a post-hoc exploratory analysis with time-dependent Cox regression to assess the effects of colonisation pressure on acquisition. We did the analyses with STATA (version 11), and SPSS (version 17).</p><p>This study is registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="interrefs30">ClinicalTrials.gov</ext-link>, number <ext-link ext-link-type="uri" xlink:href="ctgov:NCT00976638" id="interrefs40">NCT00976638</ext-link>.</p></sec><sec id="cesec70"><title>Role of the funding source</title><p>The sponsors had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p></sec></sec><sec sec-type="results" id="cesec80"><title>Results</title><p>We screened 14&#x02008;390 patients for eligibility, of whom 8976 were admitted to the ICU for at least 3 days (<xref rid="tbl1" ref-type="table">table 1</xref>). 8519 patients had at least one nasal, rectal, or wound swab during ICU admission and were therefore analysed (<xref rid="fig1" ref-type="fig">figure 1</xref>, <xref rid="tbl2" ref-type="table">table 2</xref>). ICUs varied from completely open to all single-patient rooms.</p><p>We obtained at least one nasal swab from 8517 (95%) of 8976 patients, a perineal swab from 8501 (95%) of 8976 patients, and a wound swab from 931 (10%) of 8976 patients. Of 41&#x02008;558 hand hygiene opportunities, mean compliance was 52% in phase 1, 69% in phase 2, and 77% in phase 3 (<xref rid="fig2" ref-type="fig">figure 2</xref>, <xref rid="sec1" ref-type="sec">appendix p 11</xref>). We found no evidence of a change of behaviour of health-care workers as a result of observation (ie, the Hawthorne effect; data not shown). Based on 1188 point-prevalence measurements, median adherence to chlorhexidine body-washing was 0% in phase 1, 100% in phase 2, and 100% in phase 3 (<xref rid="sec1" ref-type="sec">appendix</xref>).</p><p>In ICUs assigned to rapid screening, proportions of patients for whom contact precautions were taken increased for all antimicrobial-resistant bacteria compared with phase 2. In ICUs assigned to conventional screening, only MRSA-related and VRE-related contact precautions increased, consistent with protocol (<xref rid="sec1" ref-type="sec">appendix</xref>). The proportion of patients in single rooms varied from 15% to 22%. This proportion exceeds the proportion of carriers, which was less than 10% except during phase 3 in the rapid screening group (13%). Therefore, the scarcity of single rooms was unlikely to have decreased the quality of isolation procedures during phase 3. In phase 3, median turn-around time was 48 h for chromogenic tests, and 24 h for PCR (<xref rid="sec1" ref-type="sec">appendix</xref>, <xref rid="tbl3" ref-type="table">table 3</xref>).</p><p>We analysed 64&#x02008;997 swabs in total. At admission to ICU, 296 (3&#x000b7;6%) of 8184 patients were colonised with MRSA, 384 (4&#x000b7;7%) of 8243 were colonised with VRE, and 1014 (12&#x000b7;8%) of 7943 were colonised with HRE. Molecular analysis of first isolates at the central laboratory confirmed identification for 508 of 553 (92%) isolates for MRSA. For VRE, 346 of 672 (51%) isolates were <italic>vanA</italic> or <italic>vanB</italic> containing <italic>Enterococcus faecium</italic> and <italic>Enterococcus faecalis</italic>, and 235 (35%) were <italic>Enterococcus gallinarum</italic> and <italic>Enterococcus casseliflavus</italic>. Of 2129 HRE isolates, 1966 (92%) produced extended-spectrum &#x003b2; lactamases, of which 571 (29%) were also resistant to carbapenems, and 241 (12%) produced AmpC.</p><p>The baseline acquisition rate of antimicrobial-resistant bacteria and trends varied widely between centres (<xref rid="sec1" ref-type="sec">appendix</xref>), with a baseline trend (weekly incidence rate ratio) of 1&#x000b7;014 (95% CI 0&#x000b7;996&#x02013;1&#x000b7;031; <xref rid="tbl3" ref-type="table">table 3</xref>). Trend in acquisition of antimicrobial-resistant bacteria decreased during phase 2 with no evidence of a stepwise change in incidence between phases 1 and 2. For phase 3, there was no incremental effect on acquisition of antimicrobial-resistant bacteria (<xref rid="tbl3" ref-type="table">table 3</xref>, <xref rid="fig3" ref-type="fig">figure 3</xref>). When comparing the rapid and conventional screening groups, we found no evidence of differences in trends of acquisition of antimicrobial-resistant bacteria, though there was evidence of a stepwise difference in the rapid screening group associated with a higher acquisition rate (<xref rid="tbl3" ref-type="table">table 3</xref>). However, using a combined test of both possible effects (step changes and changes to trend), we found no strong evidence to reject the null hypothesis of no overall difference between rapid and conventional groups (p=0&#x000b7;06; likelihood ratio test).</p><p>Trends in acquisition of MRSA rose during phase 1 and fell during phase 2, resulting in a mean weekly decrease of 3&#x000b7;6%, with no substantial step change in phase 2. No substantial step change occurred during phase 3, while trends in MRSA acquisition increased (<xref rid="tbl3" ref-type="table">table 3</xref>). Step changes and changes in trends of MRSA acquisition were similar in the conventional screening and rapid screening groups (<xref rid="tbl3" ref-type="table">table 3</xref>, <xref rid="sec1" ref-type="sec">appendix</xref>). For HRE and VRE, we found no evidence of step changes in acquisition or trends in either phase 2 or phase 3; acquisition in each screening group was also much the same (<xref rid="tbl3" ref-type="table">table 3</xref>, <xref rid="sec1" ref-type="sec">appendix</xref>). Cox regression confirmed the results of the Poisson model and suggested that trends in acquisition during each phase could not be wholly explained by changes in colonisation pressure. This analysis also provided some evidence that the phase 2 intervention led to a trend for reduced acquisition of VRE (<xref rid="sec1" ref-type="sec">appendix</xref>). Much the same results were obtained for only MRSA and VRE grouped together in an unplanned post-hoc analysis (data not shown).</p><p>The total number of ICU-acquired first bacteraemias recorded during the trial was 72 HRE, 28 MRSA, and nine VRE (<italic>E faecium</italic> and <italic>E faecalis</italic> only). Overall ICU-acquired bacteraemia caused by antimicrobial-resistant bacteria did not differ significantly between phases or between intervention groups in phase 3 (<xref rid="sec1" ref-type="sec">appendix</xref>). The trend in ICU-acquisition of HRE bacteraemia fell in phase 1, but not in phase 2, phase 3, or in the screening groups. For MRSA and VRE, numbers were too low to do statistical analyses.</p><p>Mean length of stay in ICU for patients at risk for acquisition of antimicrobial-resistant bacteria was 8 days in phase 1. Trend in phase 2 was 0&#x000b7;988 (95% CI 0&#x000b7;982&#x02013;0&#x000b7;994); a net reduction of 26% (16&#x02013;48) at the end of phase 2. For phase 3, trend for length of stay in ICU was 1&#x000b7;180 (95% CI 1&#x000b7;006&#x02013;1&#x000b7;384) for ICUs using rapid screening compared with 1&#x000b7;082 (0&#x000b7;921&#x02013;1&#x000b7;270) for those using conventional screening. Rapid screening, but not conventional screening, was also associated with a stepwise increase for phase 3. There was no evidence that hospital length of stay and mortality at day 28 were affected by any of the interventions (<xref rid="sec1" ref-type="sec">appendix</xref>). We assessed 223 MRSA isolates for <italic>qacA</italic> or <italic>qacB</italic>: we detected the genes in 14 of 110 isolates from phase 1 and in 16 of 113 isolates from phase 3 (p=0&#x000b7;75; data not shown).</p></sec><sec sec-type="discussion" id="cesec90"><title>Discussion</title><p>Improved hand hygiene combined with universal chlorhexidine body-washing was associated with reduced acquisition of antimicrobial-resistant bacteria, mainly by reduction of MRSA acquisition. The same interventions did not reduce acquisition of HRE or VRE. Implementation of contact precautions for carriers identified by either chromogenic or PCR screening had no incremental effect on acquisition. Optimum hand hygiene and universal chlorhexidine body-washing was also associated with reduced length of stay in ICU, and addition of PCR-based screening was associated with increased length of stay in ICU.</p><p>Three cluster randomised studies of ICUs in the USA have evaluated similar interventions. Huskins and colleagues<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> showed no change in acquisition of MRSA and VRE after universal screening of patients and pre-emptive isolation followed by barrier precautions for identified carriers. However, average turn-around time of admission screening was 5&#x000b7;2 days, implying that many screening results were not available before patient discharge.<xref rid="bib18 bib19 bib25" ref-type="bibr"><sup>18,19,25</sup></xref></p><p>In a cluster-crossover study of nine ICUs, Climo and coworkers<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> compared daily bathing with chlorhexidine-impregnated washcloths to non-antimicrobial washcloths. The intervention reduced acquisition of VRE, but not MRSA, and was associated with a significant reduction in primary bloodstream infections, primarily caused by a reduced incidence of coagulase-negative staphylococci bacteraemia. Moreover, the analysis did not account for clustering effects and might therefore have overestimated the statistical significance of the findings. In the third study,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> 74 ICUs were randomly assigned to one of three groups: MRSA screening and isolation; targeted decolonisation; and universal decolonisation with mupirocin nasal ointment combined with chlorhexidine body-washing. Universal decolonisation was associated with significant reductions of clinical cultures yielding MRSA, and all-cause bloodstream infections, but not MRSA bloodstream infections.</p><p>None of these studies addressed the beneficial effects of hand hygiene improvement. In our study, the gradual decrease in acquisition of antimicrobial-resistant bacteria in phase 2 coincided with a gradual increase in hand hygiene compliance, suggesting that hand hygiene improvement might have been an important component of the intervention since chlorhexidine body-washing was successfully implemented immediately in phase 2 (<xref rid="sec1" ref-type="sec">appendix</xref>). However, our study design precludes assessment of the relative importance of these two interventions.</p><p>Our findings add to the growing body of evidence that, in high endemicity settings, screening for MRSA carriage followed by implementation of barrier precautions is of little effectiveness for prevention of transmission.<xref rid="bib9 bib25 bib26 bib27 bib28" ref-type="bibr"><sup>9,25&#x02013;28</sup></xref> The failure to reduce HRE acquisitions might be explained&#x02014;at least in part&#x02014;by differences in bacterial epidemiology. Whereas HRE mainly colonise the digestive tract, MRSA and VRE can also colonise the skin and environment. Thus, patient-to-patient transmission might not be the main route of acquisition for HRE in ICUs, and other prevention methods will be needed to reduce colonisation and infections with HRE, such as antibiotic stewardship programmes or intestinal decolonisation with non-absorbable antibiotics (<xref rid="box1" ref-type="boxed-text">panel</xref>).<xref rid="bib13 bib14 bib29 bib30 bib31" ref-type="bibr"><sup>13,14,29&#x02013;31</sup></xref></p><p>Our study has some limitations. With 13 ICUs in eight countries, many differences in resistance and unit characteristics existed. However, in unplanned explanatory subgroup analyses, intervention effects did not differ significantly between wards with high and low median prevalence of MRSA, VRE, or HRE at admission. Furthermore, the effectiveness of interventions did not vary with differences according to baseline trends or levels (data not shown). The 95% CIs for primary and secondary outcomes were generally small. Because the participating ICUs represent typical ICU populations, we believe that their heterogeneity and the consistent results for high and low prevalence wards add to the external validity of our results.</p><p>Absence of screening at admission for all patients could have biased the results if missing screens did not occur at random. However, only new colonisation on day 3 or later was deemed acquired in the ICU. Of the patients admitted for at least 3 days (and thus at risk for acquisition), 95% had admission and discharge data available and at least one nasal, rectal, or wound swab during ICU stay. Of the patients admitted for at least 5 days, 96% had at least one screening swab after admission. Any such bias, if present, is therefore likely to be small.</p><p>We did not expect the large changes in length of stay, which could have affected the number of acquisitions of antimicrobial-resistant bacteria (and therefore the Poisson regression results). However, the very similar results obtained by Cox regression analysis (which takes the acquisition rate into account) suggest that changes in rates cannot be explained by changes in length of stay. Knowledge of antimicrobial-resistant bacteria carriage in phase 3 might have caused some delay in discharge of patients. The increasing length of stay during phase 3 affected both groups but was larger in the rapid screening group. This difference might be because more patients were identified as carriers in this group and such patients were identified earlier. We cannot comment on the risk of transmission of antimicrobial-resistant bacteria after ICU discharge, because it was not measured.</p><p>All participating laboratories used standardised procedures to process samples, and completed quality assessments for detection of MRSA, VRE, and HRE.<xref rid="bib20 bib21 bib22" ref-type="bibr"><sup>20&#x02013;22</sup></xref> Confirmation rates at the central laboratory were high for MRSA and HRE. For VRE only 51% of isolates contained <italic>vanA</italic> or <italic>vanB</italic>. However, analyses using only confirmed <italic>vanA</italic> or <italic>vanB</italic> data did not change our results (data not shown).</p><p>A further limitation is that improved hand hygiene combined with universal chlorhexidine body-washing was not protected by randomisation and is potentially vulnerable to maturation effects. However, the primary analysis adjusted for seasonal effects, and accounted for ICU-specific levels and trends in the baseline period. Moreover, visual inspection of MRSA outcomes in the two study groups shows a similar decrease during phase 2. Finally, patient isolations were assessed from weekly point-prevalence, and not monitored on a daily patient-level basis and adherence to contact precautions was not audited.</p><p><boxed-text id="cetextbox10"><p><bold>This online publication has been corrected. The corrected version first appeared at thelancet.com/infection on Dec 17, 2013</bold></p></boxed-text></p></sec></body><back><ref-list><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name><surname>Goldmann</surname><given-names>DA</given-names></name><name><surname>Weinstein</surname><given-names>RA</given-names></name><name><surname>Wenzel</surname><given-names>RP</given-names></name></person-group><article-title>Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership</article-title><source>JAMA</source><volume>275</volume><year>1996</year><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">8604178</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="book" id="sbref20"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>WHO guidelines on hand hygiene in health care</source><year>2009</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name><surname>Batra</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name><name><surname>Whiteley</surname><given-names>C</given-names></name><name><surname>Patel</surname><given-names>AK</given-names></name><name><surname>Wyncoll</surname><given-names>D</given-names></name><name><surname>Edgeworth</surname><given-names>JD</given-names></name></person-group><article-title>Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant <italic>Staphylococcus aureus</italic> in an intensive care unit</article-title><source>Clin Infect Dis</source><volume>50</volume><year>2010</year><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">20001537</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name><surname>Climo</surname><given-names>MW</given-names></name><name><surname>Sepkowitz</surname><given-names>KA</given-names></name><name><surname>Zuccotti</surname><given-names>G</given-names></name></person-group><article-title>The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant <italic>Staphylococcus aureus</italic>, vancomycin-resistant <italic>Enterococcus</italic>, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial</article-title><source>Crit Care Med</source><volume>37</volume><year>2009</year><fpage>1858</fpage><lpage>1865</lpage><pub-id pub-id-type="pmid">19384220</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sbref50"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>IM</given-names></name><name><surname>MacKenzie</surname><given-names>FM</given-names></name><name><surname>MacLennan</surname><given-names>G</given-names></name><name><surname>Pacitti</surname><given-names>D</given-names></name><name><surname>Watson</surname><given-names>EJ</given-names></name><name><surname>Noble</surname><given-names>DW</given-names></name></person-group><article-title>Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant <italic>Staphylococcus aureus</italic> in an intensive care unit</article-title><source>Int J Antimicrob Ag</source><volume>29</volume><year>2007</year><fpage>536</fpage><lpage>543</lpage></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref60"><person-group person-group-type="author"><name><surname>Raineri</surname><given-names>E</given-names></name><name><surname>Crema</surname><given-names>L</given-names></name><name><surname>De Silvestri</surname><given-names>A</given-names></name></person-group><article-title>Meticillin-resistant <italic>Staphylococcus aureus</italic> control in an intensive care unit: a 10 year analysis</article-title><source>J Hosp Infect</source><volume>67</volume><year>2007</year><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">17945395</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref70"><person-group person-group-type="author"><name><surname>O'Horo</surname><given-names>JC</given-names></name><name><surname>Silva</surname><given-names>GLM</given-names></name><name><surname>Munoz-Price</surname><given-names>LS</given-names></name><name><surname>Safdar</surname><given-names>N</given-names></name></person-group><article-title>The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis</article-title><source>Infect Control Hosp Epidemiol</source><volume>33</volume><year>2012</year><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">22314063</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sbref80"><person-group person-group-type="author"><name><surname>Climo</surname><given-names>MW</given-names></name><name><surname>Yokoe</surname><given-names>DS</given-names></name><name><surname>Warren</surname><given-names>DK</given-names></name></person-group><article-title>Effect of daily chlorhexidine bathing on hospital-acquired infection</article-title><source>N Engl J Med</source><volume>368</volume><year>2013</year><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">23388005</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref90"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SS</given-names></name><name><surname>Septimus</surname><given-names>E</given-names></name><name><surname>Kleinman</surname><given-names>K</given-names></name></person-group><article-title>Targeted versus universal decolonization to prevent ICU infection</article-title><source>N Engl J Med</source><volume>368</volume><year>2013</year><fpage>2255</fpage><lpage>2265</lpage><pub-id pub-id-type="pmid">23718152</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref100"><person-group person-group-type="author"><name><surname>Montecalvo</surname><given-names>MA</given-names></name><name><surname>Jarvis</surname><given-names>WR</given-names></name><name><surname>Uman</surname><given-names>J</given-names></name></person-group><article-title>Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting</article-title><source>Ann Intern Med</source><volume>131</volume><year>1999</year><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">10454948</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref110"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SS</given-names></name><name><surname>Yokoe</surname><given-names>DS</given-names></name><name><surname>Hinrichsen</surname><given-names>VL</given-names></name><name><surname>Spurchise</surname><given-names>LS</given-names></name><name><surname>Datta</surname><given-names>R</given-names></name><name><surname>Miroshnik</surname><given-names>IARP</given-names></name></person-group><article-title>Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant <italic>Staphylococcus aureus</italic> bacteremia</article-title><source>Clin Infect Dis</source><volume>43</volume><year>2006</year><fpage>971</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">16983607</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref120"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>BS</given-names></name></person-group><article-title>Isolation measures in the hospital management of methicillin resistant <italic>Staphylococcus aureus</italic> (MRSA): systematic review of the literature</article-title><source>BMJ</source><volume>329</volume><year>2004</year><fpage>533</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">15345626</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sbref130"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>CR</given-names></name><name><surname>Matowe</surname><given-names>L</given-names></name><name><surname>Grilli</surname><given-names>R</given-names></name><name><surname>Grimshaw</surname><given-names>JM</given-names></name><name><surname>Thomas</surname><given-names>RE</given-names></name></person-group><article-title>Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies</article-title><source>Int J Technol Assess Health Care</source><volume>19</volume><year>2003</year><fpage>613</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">15095767</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sbref140"><person-group person-group-type="author"><name><surname>Eliopoulos</surname><given-names>GM</given-names></name><name><surname>Shardell</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>AD</given-names></name></person-group><article-title>Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies</article-title><source>Clin Infect Dis</source><volume>45</volume><year>2007</year><fpage>901</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">17806059</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sbref150"><person-group person-group-type="author"><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><name><surname>Abrahantes</surname><given-names>JC</given-names></name><name><surname>Sabiiti</surname><given-names>W</given-names></name></person-group><article-title>Evaluation of chromogenic media for detection of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>J Clin Microbiol</source><volume>48</volume><year>2010</year><fpage>1040</fpage><pub-id pub-id-type="pmid">20164268</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sbref160"><person-group person-group-type="author"><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><name><surname>Haccuria</surname><given-names>K</given-names></name><name><surname>Michiels</surname><given-names>M</given-names></name></person-group><article-title>Current trends in rapid diagnostics for methicillin-resistant <italic>Staphylococcus aureus</italic> and glycopeptide-resistant enterococcus species</article-title><source>J Clin Microbiol</source><volume>46</volume><year>2008</year><fpage>1577</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">18322065</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sbref170"><person-group person-group-type="author"><name><surname>Gazin</surname><given-names>M</given-names></name><name><surname>Paasch</surname><given-names>F</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><collab>on behalf of the MOSAR WP2 and SATURN WP1 Study Teams</collab></person-group><article-title>Current trends in culture-based and molecular detection of extended-spectrum-lactamase-harboring and carbapenem-resistant Enterobacteriaceae</article-title><source>J Clin Microbiol</source><volume>50</volume><year>2012</year><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">22259207</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sbref180"><person-group person-group-type="author"><name><surname>Gazin</surname><given-names>M</given-names></name><name><surname>Lammens</surname><given-names>C</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><collab>on behalf of the MOSAR WP2 Study Team</collab></person-group><article-title>Evaluation of GeneOhm VanR and Xpert <italic>vanA</italic>/<italic>vanB</italic> molecular assays for the rapid detection of vancomycin-resistant enterococci</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>31</volume><year>2011</year><fpage>273</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">21667270</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sbref190"><person-group person-group-type="author"><name><surname>Malhotra-Kumar</surname><given-names>S</given-names></name><name><surname>Van Heirstraeten</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name></person-group><article-title>Evaluation of molecular assays for rapid detection of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>J Clin Microbiol</source><volume>48</volume><year>2010</year><fpage>4598</fpage><lpage>4601</lpage><pub-id pub-id-type="pmid">20943869</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sbref200"><person-group person-group-type="author"><name><surname>Gazin</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Derde</surname><given-names>LPG</given-names></name></person-group><article-title>Culture-based detection of methicillin-resistant <italic>Staphylococcus aureus</italic> by a network of European laboratories: an external quality assessment study</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>31</volume><year>2011</year><fpage>1765</fpage><lpage>1770</lpage><pub-id pub-id-type="pmid">22160823</pub-id></element-citation></ref><ref id="bib21"><label>21</label><mixed-citation publication-type="other" id="oref10">Gazin M, Lammens C, Derde LPG, et al. External quality assessment of culture-based detection of extended spectrum beta-lactamase producing Gram-negative bacteria by a network of European laboratories. 22nd ECCMID; March 31&#x02013;April 3, 2012; London.</mixed-citation></ref><ref id="bib22"><label>22</label><mixed-citation publication-type="other" id="oref20">Gazin M, Lammens C, Derde LPG, et al. External quality assessment of culture-based detection of vancomycin-resistant enterococci by a network of European laboratories. 22nd ECCMID; March 31&#x02013;April 3, 2012; London.</mixed-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sbref210"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>S</given-names></name></person-group><article-title>Distribution of the antiseptic resistance genes <italic>qacA, qacB</italic> and <italic>qacC</italic> in 497 methicillin-resistant and -susceptible European isolates of <italic>Staphylococcus aureus</italic></article-title><source>J Antimicrob Chemother</source><volume>47</volume><year>2001</year><fpage>896</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">11389128</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sbref220"><person-group person-group-type="author"><name><surname>Derde</surname><given-names>LPG</given-names></name><name><surname>Dautzenberg</surname><given-names>MJD</given-names></name><name><surname>Bonten</surname><given-names>MJM</given-names></name></person-group><article-title>Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review</article-title><source>Intensive Care Med</source><volume>38</volume><year>2012</year><fpage>931</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">22527065</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sbref230"><person-group person-group-type="author"><name><surname>Huskins</surname><given-names>WC</given-names></name><name><surname>Huckabee</surname><given-names>CM</given-names></name><name><surname>O'Grady</surname><given-names>NP</given-names></name></person-group><article-title>Intervention to reduce transmission of resistant bacteria in intensive care</article-title><source>N Engl J Med</source><volume>364</volume><year>2011</year><fpage>1407</fpage><lpage>1418</lpage><pub-id pub-id-type="pmid">21488763</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sbref240"><person-group person-group-type="author"><name><surname>Gurieva</surname><given-names>T</given-names></name><name><surname>Bootsma</surname><given-names>MC</given-names></name><name><surname>Bonten</surname><given-names>MJ</given-names></name></person-group><article-title>Successful Veterans Affairs initiative to prevent methicillin-resistant <italic>Staphylococcus aureus</italic> infections revisited</article-title><source>Clin Infect Dis</source><volume>54</volume><year>2012</year><fpage>1618</fpage><lpage>1620</lpage><pub-id pub-id-type="pmid">22491330</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sbref250"><person-group person-group-type="author"><name><surname>Gurieva</surname><given-names>T</given-names></name><name><surname>Bootsma</surname><given-names>MCJ</given-names></name><name><surname>Bonten</surname><given-names>MJM</given-names></name></person-group><article-title>Cost and effects of different admission screening strategies to control the spread of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>PLoS Comput Biol</source><volume>9</volume><year>2013</year><fpage>e1002874</fpage><pub-id pub-id-type="pmid">23436984</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sbref260"><person-group person-group-type="author"><name><surname>Robotham</surname><given-names>JVJ</given-names></name><name><surname>Graves</surname><given-names>NN</given-names></name><name><surname>Cookson</surname><given-names>BDB</given-names></name></person-group><article-title>Screening, isolation, and decolonisation strategies in the control of meticillin resistant <italic>Staphylococcus aureus</italic> in intensive care units: cost effectiveness evaluation</article-title><source>BMJ</source><volume>343</volume><year>2010</year><fpage>d5694</fpage><comment>94</comment><pub-id pub-id-type="pmid">21980062</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sbref270"><person-group person-group-type="author"><name><surname>de Smet</surname><given-names>AMGA</given-names></name><name><surname>Kluytmans</surname><given-names>JAJW</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name></person-group><article-title>Decontamination of the digestive tract and oropharynx in ICU patients</article-title><source>N Engl J Med</source><volume>360</volume><year>2009</year><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19118302</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sbref280"><person-group person-group-type="author"><name><surname>Oostdijk</surname><given-names>EAN</given-names></name><name><surname>de Smet</surname><given-names>AMGA</given-names></name><name><surname>Blok</surname><given-names>HEM</given-names></name></person-group><article-title>Ecological effects of selective decontamination on resistant gram-negative bacterial colonization</article-title><source>Am J Respir Crit Care Med</source><volume>181</volume><year>2010</year><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">19965807</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sbref290"><person-group person-group-type="author"><name><surname>Oostdijk</surname><given-names>EAN</given-names></name><name><surname>de Smet</surname><given-names>AMGA</given-names></name><name><surname>Kesecioglu</surname><given-names>J</given-names></name><name><surname>Bonten</surname><given-names>MJM</given-names></name><collab>Dutch SOD-SDD Trialists Group</collab></person-group><article-title>Decontamination of cephalosporin-resistant Enterobacteriaceae during selective digestive tract decontamination in intensive care units</article-title><source>J Antimicrob Chemother</source><volume>67</volume><year>2012</year><fpage>2250</fpage><lpage>2253</lpage><pub-id pub-id-type="pmid">22643189</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="book" id="sbref300"><person-group person-group-type="author"><name><surname>Glick</surname><given-names>SB</given-names></name><name><surname>Samson</surname><given-names>DJ</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Vats</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>S</given-names></name><name><surname>Aronson</surname><given-names>N</given-names></name></person-group><source>Screening for methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA)</source><year>2013</year><publisher-name>Agency for Healthcare Research and Quality (US)</publisher-name><publisher-loc>Rockville (MD)</publisher-loc></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sbref310"><person-group person-group-type="author"><name><surname>Camus</surname><given-names>C</given-names></name><name><surname>Bellissant</surname><given-names>E</given-names></name><name><surname>Legras</surname><given-names>A</given-names></name></person-group><article-title>Randomized comparison of 2 protocols to prevent acquisition of methicillin-resistant <italic>Staphylococcus aureus</italic>: results of a 2-center study involving 500 patients</article-title><source>Infect Control Hosp Epidemiol</source><volume>32</volume><year>2011</year><fpage>1064</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">22011532</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sbref320"><person-group person-group-type="author"><name><surname>Afonso</surname><given-names>E</given-names></name><name><surname>Llaurad&#x000f3;</surname><given-names>M</given-names></name><name><surname>Gallart</surname><given-names>E</given-names></name></person-group><article-title>The value of chlorhexidine gluconate wipes and prepacked washcloths to prevent the spread of pathogens&#x02014;a systematic review</article-title><source>Aust Crit Care</source><year>2013</year><comment>published online July 1.</comment></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sbref330"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>AC</given-names></name></person-group><article-title>Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review</article-title><source>J Hosp Infect</source><volume>82</volume><year>2012</year><fpage>71</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">22889522</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sbref340"><person-group person-group-type="author"><name><surname>Cepeda</surname><given-names>JA</given-names></name><name><surname>Whitehouse</surname><given-names>T</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name></person-group><article-title>Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units: prospective two-centre study</article-title><source>Lancet</source><volume>365</volume><year>2005</year><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">15664224</pub-id></element-citation></ref></ref-list><sec id="sec1" sec-type="supplementary-material"><title>Supplementary Material</title><p><supplementary-material content-type="local-data" id="ecomp10"><caption><title>Supplementary appendix</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material></p></sec><ack id="ceack10"><sec><title>Acknowledgments</title><p>This study was supported by the <funding-source id="GS1">European Commission under the Life Science Health Priority of the 6th Framework Program</funding-source> (MOSAR network contract LSHP-CT-2007-037941). MJMB was supported by the <funding-source id="GS2">Netherlands Organization of Scientific Research</funding-source> (VICI NWO Grant 918.76.611). BSC was supported by <funding-source id="GS3">The Oak Foundation and The Medical Research Council and Department for International Development</funding-source> (grant number MR/K006924/1) and works within the Wellcome Trust&#x02013;Mahidol University&#x02013;Oxford Tropical Medicine Research Programme supported by the <funding-source id="GS4">Wellcome Trust</funding-source> (089275/Z/09/Z). We thank B Allegranzi and A Agostinho for training assistance and materials.</p></sec></ack><ack><title>Contributors</title><p>MJMB, CB-B, BSC, and LPGD designed the study. MJMB and CB-B supervised the study. LPGD searched the published work and supervised data collection. BSC and LPGD provided the figures. MJMB, CB-B, BSC, MJDD, and LPGD analysed and interpreted data. MJMB, CB-B, BSC, and LPGD wrote the report. All other authors collected and interpreted data, and helped to revise the report.</p></ack><ack><title>Participating staff</title><p><italic>Data collection</italic>&#x02014;E Aires, A Antoniadou, A Armaganidis, F Blairon, J Carneiro, D Chaskou, P Coppadoro, A-P Dias, I Drinovec, M Elia, V Exarchou, A Flet, J Fournier, N Gillet, A Jakli&#x0010d;, M Jereb, A Kane, E Karkali, J Kieffer, P Kirpach, C Landelle, F Landercy, C Lawrence, P Legrand, V Lopes, E Magira, F Marco, J A Mart&#x000ed;nez, A Melb&#x00101;rde-Kelmere, B Misset, R Monte, E Moreno, J C Nguyen, M Novak, D Orazi, E Papadomichelakis, J Papaparaskevas, M Paris, J Pavleas, F Pimenta, R Pi&#x000f1;er, A Radouan, M-G Ramunno, M Reis, I Rinaldi, E Ronco, A San Jose, K Seme, A Skiada, S Trapassi, M Tronci, M Verachten, J Vila, K Vrankar, M Winkler, S Zagavierou; <italic>data monitoring and collection</italic>&#x02014;M Hopman; <italic>data management</italic>&#x02014;F Leus, J Schotsman, J Zwerver.</p></ack><ack><title>Conflicts of interest</title><p>We declare that we have no conflicts of interest.</p></ack></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Study profile</p><p>Patients at risk for acquiring colonisation with AMRB excludes all patients colonised at admission with any of MRSA, VRE, HRE, or in whom a first (admission) swab was taken after the first 2 days of ICU stay and was positive. AMRB=antimicrobial-resistant bacteria. ICU=intensive care unit. MRSA=meticillin-resistant <italic>Staphylococcus aureus</italic>. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. *Admitted for at least 3 days, for whom admission and discharge data were available and of whom at least one nasal, rectal, or wound swab was obtained during ICU admission.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Mean hand hygiene compliance per month</p><p>Hand hygiene improvement intervention introduced at month 0. Error bars are 95% CIs.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Acquisition of antimicrobial-resistant bacteria and meticillin-resistant <italic>Staphylococcus aureus</italic> per 100 patient-days at risk</p><p>For all antimicrobial bacteria in both screening groups (A), for MRSA in both screening groups (B), for all antimicrobial bacteria in the conventional screening group (C), for MRSA in the conventional screening group (D), for all antimicrobial bacteria in the rapid screening group (E), and for MRSA in the rapid screening group (F). Shaded area is the start of phase 3. Green dots are data; green lines are 7 week moving average. Red lines are expected values from the multilevel Poisson segmented regression model. Cluster effects were accounted for, and potential confounding factors (sex, age, month, invasive devices, nurse-to-patient staffing ratio, location before ICU admission, reason for admission, APACHE and SAPS score, hospital, and number of days-at-risk for acquisition) were fitted as covariates. APACHE=Acute Physiology and Chronic Health Evaluation. SAPS=Simplified Acute Physiology Score.</p></caption><graphic xlink:href="gr3"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left"><bold>Phase 1 (n=2043)</bold></th><th align="left"><bold>Phase 2 (n=2072)</bold></th><th colspan="2" align="left"><bold>Phase 3</bold><hr/></th></tr><tr><th/><th/><th/><th align="left">Conventional screening group (n=2348)</th><th align="left">Rapid screening group (n=2513)</th></tr></thead><tbody><tr><td colspan="5" align="left"><bold>ICU characteristics</bold></td></tr><tr><td align="left">Beds occupied</td><td align="left">84&#x000b7;7% (18&#x000b7;5)</td><td align="left">87&#x000b7;9% (16&#x000b7;6)</td><td align="left">84&#x000b7;2% (17&#x000b7;1)</td><td align="left">86&#x000b7;6% (18&#x000b7;3)</td></tr><tr><td align="left">Nurse:patient ratio</td><td align="left">0&#x000b7;55 (0&#x000b7;22)</td><td align="left">0&#x000b7;53 (0&#x000b7;19)</td><td align="left">0&#x000b7;55 (0&#x000b7;20)</td><td align="left">0&#x000b7;55 (0&#x000b7;25)</td></tr><tr><td colspan="5" align="left"><bold>Location before admission to ICU</bold></td></tr><tr><td align="left">Home or private residence</td><td align="left">38&#x000b7;2% (36&#x000b7;1&#x02013;40&#x000b7;4)</td><td align="left">35&#x000b7;6% (33&#x000b7;6&#x02013;37&#x000b7;7)</td><td align="left">38&#x000b7;2% (36&#x000b7;3&#x02013;40&#x000b7;2)</td><td align="left">37&#x000b7;2% (35&#x000b7;3&#x02013;39&#x000b7;1)</td></tr><tr><td align="left">Health-care facility</td><td align="left">59&#x000b7;1% (56&#x000b7;9&#x02013;61&#x000b7;2)</td><td align="left">60&#x000b7;3% (58&#x000b7;1&#x02013;62&#x000b7;4)</td><td align="left">58&#x000b7;6% (56&#x000b7;6&#x02013;60&#x000b7;6<bold>)</bold></td><td align="left">58&#x000b7;6% (56&#x000b7;6&#x02013;60&#x000b7;5)</td></tr><tr><td align="left">Unknown or other</td><td align="left">2&#x000b7;7% (2&#x000b7;1&#x02013;3&#x000b7;5)</td><td align="left">4&#x000b7;2% (3&#x000b7;4&#x02013;5&#x000b7;1)</td><td align="left">3&#x000b7;2% (2&#x000b7;6&#x02013;4&#x000b7;0)</td><td align="left">4&#x000b7;3% (3&#x000b7;6&#x02013;5&#x000b7;1)</td></tr><tr><td colspan="5" align="left"><bold>Risk factors for colonisation before admission to ICU</bold></td></tr><tr><td align="left">Admitted to a hospital for &#x0003e;24 h in the past year</td><td align="left">52&#x000b7;6% (50&#x000b7;4&#x02013;54&#x000b7;8)</td><td align="left">47&#x000b7;6% (45&#x000b7;4&#x02013;49&#x000b7;7)</td><td align="left">56&#x000b7;6% (54&#x000b7;5&#x02013;58&#x000b7;6)</td><td align="left">41&#x000b7;4% (39&#x000b7;4&#x02013;43&#x000b7;3)</td></tr><tr><td align="left">Any type of surgery in the past year</td><td align="left">20&#x000b7;3% (18&#x000b7;6&#x02013;22&#x000b7;1)</td><td align="left">22&#x000b7;2% (20&#x000b7;4&#x02013;24&#x000b7;0)</td><td align="left">20&#x000b7;9% (19&#x000b7;3&#x02013;22&#x000b7;6)</td><td align="left">18&#x000b7;9% (17&#x000b7;4&#x02013;20&#x000b7;5)</td></tr><tr><td align="left">Urgent or emergency surgery before admission to ICU</td><td align="left">17&#x000b7;4% (15&#x000b7;8&#x02013;19&#x000b7;1)</td><td align="left">15&#x000b7;3% (13&#x000b7;8&#x02013;17&#x000b7;0)</td><td align="left">14&#x000b7;8% (13&#x000b7;4&#x02013;16&#x000b7;3)</td><td align="left">17&#x000b7;4% (16&#x000b7;0&#x02013;19&#x000b7;0)</td></tr><tr><td colspan="5" align="left"><bold>Patient history</bold></td></tr><tr><td align="left">Solid tumour</td><td align="left">14&#x000b7;2% (12&#x000b7;8&#x02013;15&#x000b7;8)</td><td align="left">12&#x000b7;0% (10&#x000b7;7&#x02013;13&#x000b7;5)</td><td align="left">13&#x000b7;5% (12&#x000b7;2&#x02013;14&#x000b7;9)</td><td align="left">15&#x000b7;8% (14&#x000b7;5&#x02013;17&#x000b7;3)</td></tr><tr><td align="left">Haematological cancer</td><td align="left">3&#x000b7;9% (3&#x000b7;2&#x02013;4&#x000b7;9)</td><td align="left">4&#x000b7;1% (3&#x000b7;3&#x02013;5&#x000b7;0)</td><td align="left">4&#x000b7;2% (3&#x000b7;4&#x02013;5&#x000b7;1)</td><td align="left">4&#x000b7;1% (3&#x000b7;4&#x02013;4&#x000b7;9)</td></tr><tr><td align="left">Haemopoietic stem cell or bone marrow transplant</td><td align="left">0&#x000b7;7% (0&#x000b7;4&#x02013;1&#x000b7;2)</td><td align="left">0&#x000b7;8% (0&#x000b7;5&#x02013;1&#x000b7;3)</td><td align="left">0&#x000b7;8% (0&#x000b7;5&#x02013;1&#x000b7;3)</td><td align="left">0&#x000b7;8% (0&#x000b7;5&#x02013;1&#x000b7;2)</td></tr><tr><td align="left">Solid organ transplant</td><td align="left">2&#x000b7;2% (1&#x000b7;6&#x02013;2&#x000b7;9)</td><td align="left">1&#x000b7;6% (1&#x000b7;2&#x02013;2&#x000b7;3)</td><td align="left">1&#x000b7;8% (1&#x000b7;4&#x02013;2&#x000b7;5)</td><td align="left">1&#x000b7;5% (1&#x000b7;1&#x02013;2&#x000b7;0)</td></tr><tr><td align="left">HIV/AIDS</td><td align="left">1&#x000b7;9% (1&#x000b7;4&#x02013;2&#x000b7;5)</td><td align="left">1&#x000b7;4% (0&#x000b7;9&#x02013;2&#x000b7;0)</td><td align="left">1&#x000b7;4% (1&#x000b7;0&#x02013;2&#x000b7;0)</td><td align="left">1&#x000b7;6% (1&#x000b7;2&#x02013;2&#x000b7;2)</td></tr><tr><td align="left">MRSA colonisation in the past year</td><td align="left">3&#x000b7;1% (2&#x000b7;2&#x02013;3&#x000b7;6)</td><td align="left">3&#x000b7;1% (2&#x000b7;4&#x02013;4&#x000b7;0)</td><td align="left">2&#x000b7;8% (2&#x000b7;2&#x02013;3&#x000b7;6)</td><td align="left">4&#x000b7;5% (3&#x000b7;8&#x02013;5&#x000b7;4)</td></tr><tr><td align="left">VRE colonisation in the past year</td><td align="left">0&#x000b7;2% (0&#x000b7;1&#x02013;0&#x000b7;4)</td><td align="left">0&#x000b7;2% (0&#x000b7;1&#x02013;0&#x000b7;6)</td><td align="left">0&#x000b7;2% (0&#x000b7;1&#x02013;0&#x000b7;5)</td><td align="left">2&#x000b7;1% (1&#x000b7;6&#x02013;2&#x000b7;7)</td></tr><tr><td align="left">HRE colonisation in the past year</td><td align="left">2&#x000b7;3% (1&#x000b7;7&#x02013;3&#x000b7;1)</td><td align="left">2&#x000b7;7% (2&#x000b7;1&#x02013;3&#x000b7;4)</td><td align="left">3&#x000b7;2% (2&#x000b7;5&#x02013;3&#x000b7;9)</td><td align="left">3&#x000b7;0% (2&#x000b7;4&#x02013;3&#x000b7;7)</td></tr><tr><td colspan="5" align="left"><bold>Patient demographics</bold></td></tr><tr><td align="left">Median age (IQR, years)</td><td align="left">65 (50&#x02013;76)</td><td align="left">64 (50&#x02013;75)</td><td align="left">64 (49&#x02013;76)</td><td align="left">65 (51&#x02013;77)</td></tr><tr><td align="left">Men</td><td align="left">61&#x000b7;0% (58&#x000b7;9&#x02013;63&#x000b7;1)</td><td align="left">60&#x000b7;0% (57&#x000b7;9&#x02013;62&#x000b7;1)</td><td align="left">60&#x000b7;9% (58&#x000b7;9&#x02013;62&#x000b7;9)</td><td align="left">59&#x000b7;3% (57&#x000b7;4&#x02013;61&#x000b7;2)</td></tr><tr><td align="left">Non-surgical reason for admission to ICU</td><td align="left">76&#x000b7;5% (74&#x000b7;6&#x02013;78&#x000b7;3)</td><td align="left">79&#x000b7;8% (78&#x000b7;0&#x02013;81&#x000b7;5)</td><td align="left">81&#x000b7;4% (79&#x000b7;8&#x02013;82&#x000b7;9)</td><td align="left">73&#x000b7;4% (71&#x000b7;7&#x02013;75&#x000b7;1)</td></tr><tr><td align="left">Median APACHE-II score (IQR)<xref rid="tbl1fn1" ref-type="table-fn">*</xref></td><td align="left">16 (11&#x02013;22)</td><td align="left">16 (11&#x02013;22)</td><td align="left">15 (10&#x02013;22)</td><td align="left">15 (11&#x02013;19)</td></tr><tr><td align="left">Median SAPS-II (IQR)<xref rid="tbl1fn2" ref-type="table-fn">&#x02020;</xref></td><td align="left">40 (28&#x02013;54)</td><td align="left">38 (27&#x02013;50)</td><td align="left">37 (26&#x02013;50)</td><td align="left">35 (24&#x02013;48)</td></tr><tr><td colspan="5" align="left"><bold>Invasive devices (during first 3 days)</bold></td></tr><tr><td align="left">Endotracheal tube</td><td align="left">60&#x000b7;4% (58&#x000b7;2&#x02013;62&#x000b7;5)</td><td align="left">60&#x000b7;4% (58&#x000b7;3&#x02013;62&#x000b7;5)</td><td align="left">59&#x000b7;4% (57&#x000b7;4&#x02013;61&#x000b7;3)</td><td align="left">52&#x000b7;1% (50&#x000b7;2&#x02013;54&#x000b7;1)</td></tr><tr><td align="left">Tracheostomy tube</td><td align="left">4&#x000b7;2% (3&#x000b7;4&#x02013;5&#x000b7;2)</td><td align="left">4&#x000b7;3% (3&#x000b7;5&#x02013;5&#x000b7;3)</td><td align="left">3&#x000b7;2% (2&#x000b7;6&#x02013;4&#x000b7;0)</td><td align="left">5&#x000b7;8% (5&#x000b7;0&#x02013;6&#x000b7;8)</td></tr><tr><td align="left">Central venous catheter</td><td align="left">69&#x000b7;8% (67&#x000b7;7&#x02013;71&#x000b7;7)</td><td align="left">68&#x000b7;3% (66&#x000b7;3&#x02013;70&#x000b7;3)</td><td align="left">61&#x000b7;5% (59&#x000b7;5&#x02013;63&#x000b7;5)</td><td align="left">73&#x000b7;5% (71&#x000b7;7&#x02013;75&#x000b7;2)</td></tr><tr><td align="left">Arterial intravascular catheter</td><td align="left">64&#x000b7;2% (62&#x000b7;1&#x02013;66&#x000b7;3)</td><td align="left">63&#x000b7;4% (61&#x000b7;3&#x02013;65&#x000b7;5)</td><td align="left">59&#x000b7;2% (57&#x000b7;2&#x02013;61&#x000b7;2)</td><td align="left">69&#x000b7;0% (67&#x000b7;2&#x02013;70&#x000b7;8)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean (95% CI), unless otherwise stated. Data were taken from all patients admitted for at least 3 days. ICU=intensive care unit. APACHE=Acute Physiology and Chronic Health Evaluation. SAPS=Simplified Acute Physiology Score. MRSA=meticillin-resistant <italic>Staphylococcus aureus</italic>. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn1"><label>*</label><p>Data available for 709 patients in phase 1, 780 in phase 2, and 1724 in phase 3.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn2"><label>&#x02020;</label><p>Data available for 1334 patients in phase 1, 1292 in phase 2, and 3134 in phase 3.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Carriage of antimicrobial-resistant bacteria at admission to ICU</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th align="left"><bold>Phase 1</bold></th><th align="left"><bold>Phase 2</bold></th><th align="left"><bold>Phase 3</bold></th></tr></thead><tbody><tr><td colspan="3" align="left">At ICUs using conventional screening</td><td align="left">n=979</td><td align="left">n=1020</td><td align="left">n=2280</td></tr><tr><td/><td colspan="2" align="left">Any (%)</td><td align="left">13&#x000b7;5% (11&#x000b7;5&#x02013;15&#x000b7;8)</td><td align="left">12&#x000b7;5% (10&#x000b7;6&#x02013;14&#x000b7;6)</td><td align="left">10&#x000b7;3% (9&#x000b7;1&#x02013;11&#x000b7;6)</td></tr><tr><td/><td colspan="2" align="left">MRSA (%)</td><td align="left">5&#x000b7;4% (4&#x000b7;2&#x02013;7&#x000b7;0)</td><td align="left">3&#x000b7;7% (2&#x000b7;7&#x02013;5&#x000b7;1)</td><td align="left">4&#x000b7;1% (3&#x000b7;3&#x02013;5&#x000b7;0)</td></tr><tr><td/><td colspan="2" align="left">VRE (%)</td><td align="left">3&#x000b7;3% (2&#x000b7;3&#x02013;4&#x000b7;6)</td><td align="left">2&#x000b7;9% (2&#x000b7;1&#x02013;4&#x000b7;2)</td><td align="left">1&#x000b7;1% (0&#x000b7;7&#x02013;1&#x000b7;6)</td></tr><tr><td/><td colspan="5" align="left">HRE</td></tr><tr><td/><td/><td align="left">Total (%)</td><td align="left">6&#x000b7;8% (5&#x000b7;4&#x02013;8&#x000b7;6)</td><td align="left">7&#x000b7;0% (5&#x000b7;6&#x02013;8&#x000b7;7)</td><td align="left">6&#x000b7;0% (5&#x000b7;1&#x02013;7&#x000b7;1)</td></tr><tr><td/><td/><td align="left"><italic>Escherichia coli</italic> (%)</td><td align="left">4&#x000b7;0% (2&#x000b7;9&#x02013;5&#x000b7;4)</td><td align="left">2&#x000b7;8% (2&#x000b7;0&#x02013;4&#x000b7;1)</td><td align="left">3&#x000b7;7% (3&#x000b7;0&#x02013;4&#x000b7;5)</td></tr><tr><td/><td/><td align="left"><italic>Proteus, Providencia</italic>, or <italic>Morganella</italic> spp (%)</td><td align="left">0&#x000b7;3% (0&#x000b7;1&#x02013;0&#x000b7;9)</td><td align="left">0&#x000b7;4% (0&#x000b7;2&#x02013;1&#x000b7;0)</td><td align="left">0&#x000b7;2% (0&#x000b7;1&#x02013;0&#x000b7;5)</td></tr><tr><td/><td/><td align="left"><italic>Klebsiella, Enterobacter, Serratia</italic>, or <italic>Citrobacter</italic> spp (%)</td><td align="left">3&#x000b7;4% (2&#x000b7;4&#x02013;4&#x000b7;7)</td><td align="left">4&#x000b7;8% (3&#x000b7;7&#x02013;6&#x000b7;3)</td><td align="left">2&#x000b7;7% (2&#x000b7;1&#x02013;3&#x000b7;4)</td></tr><tr><td colspan="3" align="left">At ICUs using rapid screening</td><td align="left">n=983</td><td align="left">n=906</td><td align="left">n=2351</td></tr><tr><td/><td colspan="2" align="left">Any (%)</td><td align="left">12&#x000b7;3% (10&#x000b7;4&#x02013;14&#x000b7;5)</td><td align="left">11&#x000b7;0% (9&#x000b7;2&#x02013;13&#x000b7;2)</td><td align="left">14&#x000b7;1% (12&#x000b7;7&#x02013;15&#x000b7;5)</td></tr><tr><td/><td colspan="2" align="left">MRSA (%)</td><td align="left">3&#x000b7;3% (2&#x000b7;3&#x02013;4&#x000b7;6)</td><td align="left">4&#x000b7;6% (3&#x000b7;5&#x02013;6&#x000b7;2)</td><td align="left">3&#x000b7;3% (2&#x000b7;6&#x02013;4&#x000b7;1)</td></tr><tr><td/><td colspan="2" align="left">VRE (%)</td><td align="left">3&#x000b7;5% (2&#x000b7;5&#x02013;4&#x000b7;8)</td><td align="left">2&#x000b7;2% (1&#x000b7;4&#x02013;3&#x000b7;4)</td><td align="left">5&#x000b7;8% (4&#x000b7;9&#x02013;6&#x000b7;8)</td></tr><tr><td/><td colspan="5" align="left">HRE</td></tr><tr><td/><td/><td align="left">Total (%)</td><td align="left">7&#x000b7;0% (5&#x000b7;6&#x02013;8&#x000b7;8)</td><td align="left">5&#x000b7;7% (4&#x000b7;4&#x02013;7&#x000b7;5)</td><td align="left">7&#x000b7;7% (6&#x000b7;7&#x02013;8&#x000b7;8)</td></tr><tr><td/><td/><td align="left"><italic>Escherichia coli</italic> (%)</td><td align="left">2&#x000b7;7% (1&#x000b7;9&#x02013;4&#x000b7;0)</td><td align="left">2&#x000b7;2% (1&#x000b7;4&#x02013;3&#x000b7;4)</td><td align="left">3&#x000b7;8% (3&#x000b7;1&#x02013;4&#x000b7;6)</td></tr><tr><td/><td/><td align="left"><italic>Proteus, Providencia</italic>, or <italic>Morganella</italic> spp (%)</td><td align="left">0&#x000b7;3% (0&#x000b7;1&#x02013;0&#x000b7;9)</td><td align="left">0&#x000b7;0% (0&#x000b7;0&#x02013;0&#x000b7;4)</td><td align="left">0&#x000b7;2% (0&#x000b7;1&#x02013;0&#x000b7;5)</td></tr><tr><td/><td/><td align="left"><italic>Klebsiella, Enterobacter, Serratia</italic>, or <italic>Citrobacter</italic> spp (%)</td><td align="left">4&#x000b7;8% (3&#x000b7;6&#x02013;6&#x000b7;3)</td><td align="left">3&#x000b7;6% (2&#x000b7;6&#x02013;5&#x000b7;1)</td><td align="left">4&#x000b7;2% (3&#x000b7;5&#x02013;5&#x000b7;1)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are mean (95% CI). Excludes patients for whom both the admission swab was not obtained during the first 2 days after admission, and the first swab taken during ICU admission was positive. MRSA=meticillin-resistant <italic>Staphylococcus aureus</italic>. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. ICU=intensive care unit.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Weekly acquisition of any antimicrobial-resistant bacteria, MRSA, VRE, and HRE</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left"><bold>Antimicrobial-resistant bacteria</bold></th><th align="left"><bold>MRSA</bold></th><th align="left"><bold>VRE</bold></th><th align="left"><bold>HRE</bold></th></tr></thead><tbody><tr><td align="left">Phase 1 trend</td><td align="left">1&#x000b7;014 (0&#x000b7;996&#x02013;1&#x000b7;031; p=0&#x000b7;12)</td><td align="left">1&#x000b7;042 (1&#x000b7;010&#x02013;1&#x000b7;075; p=0&#x000b7;01)</td><td align="left">1&#x000b7;000 (0&#x000b7;971&#x02013;1&#x000b7;030; p=0&#x000b7;99)</td><td align="left">1&#x000b7;012 (0&#x000b7;992&#x02013;1&#x000b7;032; p=0&#x000b7;25)</td></tr><tr><td align="left">Phase 2 step change</td><td align="left">0&#x000b7;955 (0&#x000b7;676&#x02013;1&#x000b7;348; p=0&#x000b7;79)</td><td align="left">1&#x000b7;159 (0&#x000b7;654&#x02013;2&#x000b7;053; p=0&#x000b7;61)</td><td align="left">0&#x000b7;884 (0&#x000b7;481&#x02013;1&#x000b7;626; p=0&#x000b7;69)</td><td align="left">0&#x000b7;831 (0&#x000b7;559&#x02013;1&#x000b7;235; p=0&#x000b7;36)</td></tr><tr><td align="left">Phase 2 change in trend</td><td align="left">0&#x000b7;976 (0&#x000b7;954&#x02013;0&#x000b7;999; p=0&#x000b7;04)</td><td align="left">0&#x000b7;925 (0&#x000b7;890&#x02013;0&#x000b7;962; p&#x0003c;0&#x000b7;001)</td><td align="left">0&#x000b7;982 (0&#x000b7;945&#x02013;1&#x000b7;020; p=0&#x000b7;36)</td><td align="left">0&#x000b7;994 (0&#x000b7;968&#x02013;1&#x000b7;021; p=0&#x000b7;66)</td></tr><tr><td align="left">Phase 3 step change</td><td align="left">0&#x000b7;634 (0&#x000b7;349&#x02013;1&#x000b7;153; p=0&#x000b7;14)</td><td align="left">0&#x000b7;755 (0&#x000b7;252&#x02013;2&#x000b7;257; p=0&#x000b7;62)</td><td align="left">0&#x000b7;651 (0&#x000b7;209&#x02013;2&#x000b7;031; p=0&#x000b7;46)</td><td align="left">0&#x000b7;525 (0&#x000b7;263&#x02013;1&#x000b7;048; p=0&#x000b7;07)</td></tr><tr><td align="left">Phase 3 change in trend</td><td align="left">1&#x000b7;015 (0&#x000b7;998&#x02013;1&#x000b7;032; p=0&#x000b7;09)</td><td align="left">1&#x000b7;057 (1&#x000b7;029&#x02013;1&#x000b7;086; p&#x0003c;0&#x000b7;001)</td><td align="left">1&#x000b7;015 (0&#x000b7;984&#x02013;1&#x000b7;048; p=0&#x000b7;34)</td><td align="left">0&#x000b7;991 (0&#x000b7;971&#x02013;1&#x000b7;011; p=0&#x000b7;35)</td></tr><tr><td align="left">Phase 3 step change (rapid <italic>vs</italic> conventional screening)</td><td align="left">1&#x000b7;696 (1&#x000b7;090&#x02013;2&#x000b7;638; p=0&#x000b7;02)</td><td align="left">1&#x000b7;734 (0&#x000b7;768&#x02013;3&#x000b7;916; p=0&#x000b7;19)</td><td align="left">1&#x000b7;735 (0&#x000b7;711&#x02013;4&#x000b7;234; p=0&#x000b7;23)</td><td align="left">1&#x000b7;691 (1&#x000b7;012&#x02013;2&#x000b7;828; p=0&#x000b7;05)</td></tr><tr><td align="left">Phase 3 change in trend (rapid <italic>vs</italic> conventional screening)</td><td align="left">0&#x000b7;996 (0&#x000b7;984&#x02013;1&#x000b7;007; p=0&#x000b7;46)</td><td align="left">0&#x000b7;985 (0&#x000b7;966&#x02013;1&#x000b7;005; p=0&#x000b7;15)</td><td align="left">0&#x000b7;993 (0&#x000b7;969&#x02013;1&#x000b7;018; p=0&#x000b7;59)</td><td align="left">1&#x000b7;000 (0&#x000b7;986&#x02013;1&#x000b7;014; p=0&#x000b7;99)</td></tr><tr><td align="left">Likelihood ratio test (rapid <italic>vs</italic> conventional screening)</td><td align="left">p=0&#x000b7;06</td><td align="left">p=0&#x000b7;34</td><td align="left">p=0&#x000b7;47</td><td align="left">p=0&#x000b7;10</td></tr></tbody></table><table-wrap-foot><fn><p>Data are IRR (95% CI) unless stated otherwise. IRR &#x0003c;1 represents a decrease in acquisition, whereas IRR &#x0003e;1 represents an increase. Cluster effects were accounted for in the analyses, and potential confounding factors (sex, age, month, invasive devices, nurse-to-patient staffing ratio, location before ICU admission, reason for admission, APACHE/SAPS, hospital, and number of days-at-risk for acquisition) were fitted as covariates. MRSA=meticillin-resistant <italic>Staphylococcus aureus</italic>. VRE=vancomycin-resistant enterococci. HRE=highly resistant Enterobacteriaceae. IRR=incidence rate ratio. APACHE=Acute Physiology and Chronic Health Evaluation. SAPS=Simplified Acute Physiology Score.</p></fn></table-wrap-foot></table-wrap><boxed-text id="box1"><label>Panel</label><caption><title>Research in context</title></caption><p><bold>Systematic review</bold></p><p>We searched PubMed with the terms (&#x0201c;clinical trials as topic&#x0201d;[MeSH Terms]) AND ((&#x0201c;anti-infective agents&#x0201d;[Pharmacological Action] OR &#x0201c;anti-infective agents&#x0201d;[MeSH Terms] OR (&#x0201c;anti-infective&#x0201d;[All Fields] AND &#x0201c;agents&#x0201d;[All Fields]) OR &#x0201c;anti-infective agents&#x0201d;[All Fields] OR &#x0201c;antimicrobial&#x0201d; AND resistance) AND (&#x0201c;intensive care&#x0201d;[MeSH Terms]) AND (&#x0201c;infection control&#x0201d;[MeSH Terms])) which returned 66 articles, of which we excluded those testing drug prophylaxis (eg, selective digestive decontamination or surgical prophylaxis) or testing prevention of specific infections (eg, catheter-related or respiratory infections) or non-resistant microorganisms and studies done outside intensive care units (ICUs). Related citations and authors' personal references lists were also searched. We identified eight articles, including four systematic reviews. One was a systematic review<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> of screening for meticillin-resistant <italic>Staphylococcus aureus</italic> (MRSA), which included 48 studies, of which 14 were done in ICUs, but did not include the most recent and largest study by Huang and colleagues.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> This meta-analysis concluded that the available evidence was insufficient to assess the effect of screening of ICU patients for MRSA carriage on MRSA acquisition, and evidence was insufficient to support or refute that, compared with no screening, screening for MRSA carriage in ICU patients decreases healthcare-associated MRSA infection or bloodstream infection. An individual-patient randomised controlled trial not included in this review found no effect of screening and isolation on MRSA acquisition rates.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> Further evidence against routine screening has been provided by the study by Huang and colleagues,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> showing no significant reduction in MRSA acquisition or bloodstream infection with screening and isolation, but reduced rates with decolonisation strategies using chlorhexidine and mupirocin. Three systematic reviews<xref rid="bib24 bib34 bib35" ref-type="bibr"><sup>24,34,35</sup></xref> of chlorhexidine bathing were done before publication of the study by Climo and coworkers,<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> the results of which favoured the intervention when studying rates of acquisition of MRSA and vancomycin-resistant enterococci, without evidence of efficacy against multidrug-resistant Gram-negative bacteria. There was only one randomised controlled trial of isolation and segregation of colonised patients, which showed no efficacy of this measure on MRSA acquisition rate.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> No controlled study addressed the effectiveness of hand hygiene or the preventive efficacy of the above measures on rates of acquisition of multidrug-resistant Gram-negative bacteria in ICU patients.</p><p><bold>Interpretation</bold></p><p>Our study addresses the effect of hand hygiene in combination with chlorhexidine bathing and of screening and isolation on the prevention of acquisition of major antimicrobial-resistant pathogens (multidrug-resistant bacteria, including MRSA, vancomycin-resistant enterococci, and highly resistant Enterobacteriaceae) in ICUs. Improved hand hygiene and chlorhexidine bathing are associated with a reduction in acquisition, mainly through reduced acquisition of MRSA, whereas no effect on highly resistant Enterobacteriaceae was evidenced. Screening and isolation of carriers did not further reduce acquisition of multidrug-resistant bacteria, whether screening was done with rapid testing or conventional testing. Our results show the efficacy of improved hand hygiene to reduce MRSA acquisition rates, and concur with other studies<xref rid="bib7 bib8" ref-type="bibr"><sup>7,8</sup></xref> of the efficacy of chlorhexidine body-washing. Our finding of a lack of added preventive efficacy of screening and isolation of carriers is also consistent with several large recent controlled studies<xref rid="bib9 bib25" ref-type="bibr"><sup>9,25</sup></xref> showing little or no efficacy of such an approach to reduce acquisition of MRSA or VRE in ICUs; however, this finding might not apply to settings with lower hand hygiene compliance. Lastly, the absence of an effect of any of our interventions on highly resistant Enterobacteriaceae suggests that new methods to control this emerging threat&#x02014;eg, selective digestive decontamination&#x02014;should be investigated.</p></boxed-text></floats-group></article>